 |
27 Diseases |  |
7 Trials |
|
7 Trials |  |
733 News |  |
| «123456789» |
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed, Monotherapy: Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes (clinicaltrials.gov) - Dec 5, 2014
P3, N=360, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed: Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin (clinicaltrials.gov) - Dec 5, 2014
P3, N=432, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed, Combination therapy: Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes (clinicaltrials.gov) - Nov 28, 2014
P3, N=292, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Victoza (liraglutide) / Novo Nordisk
Trial completion: LIRA-LIXI (clinicaltrials.gov) - Nov 23, 2014
P4, N=404, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Adlyxin (lixisenatide) / Sanofi
Enrollment open, Trial initiation date, Combination therapy: LixiBIT: Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin (clinicaltrials.gov) - Nov 18, 2014
P3, N=10, Recruiting, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014
- | Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed: Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying (clinicaltrials.gov) - Nov 13, 2014
P2, N=26, Active, not recruiting, Sponsor: Profil Institut f
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 Enrolling by invitation --> Active, not recruiting
- |||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date: LixiLan-O: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (clinicaltrials.gov) - Nov 3, 2014
P3, N=1125, Recruiting, Sponsor: Sanofi
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Aug 2015 --> May 2015
- Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment status: Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying (clinicaltrials.gov) - Oct 31, 2014
P2, N=26, Enrolling by invitation, Sponsor: Profil Institut f
Trial primary completion date: Aug 2015 --> May 2015 Recruiting --> Enrolling by invitation
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi, Apidra (insulin glulisine) / Sanofi
Biomarker, New P4 trial: ELIXIRS: Effect of LIXIsenatide on the Renal System (clinicaltrials.gov) - Oct 28, 2014
P4, N=40, Recruiting, Sponsor: VU University Medical Center
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P2 trial: Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients (clinicaltrials.gov) - Oct 24, 2014
P2, N=36, Not yet recruiting, Sponsor: Sanofi
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed, Trial primary completion date: Study on Lixisenatide and Counterregulation to Hypoglycemia (clinicaltrials.gov) - Sep 30, 2014
P4, N=18, Active, not recruiting, Sponsor: Lund University
Recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2014
- Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P1 trial: Effects of Victoza (clinicaltrials.gov) - Sep 5, 2014
P1, N=72, Not yet recruiting, Sponsor: Profil Institut f
- Adlyxin (lixisenatide) / Sanofi, Apidra (insulin glulisine) / Sanofi
Biomarker, New P4 trial: The renal effects of lixisenatide (a novel, gut-hormone based diabetes drug) and insulin glulisine (a common, wideley diabetes drug) Een onderzoek naar de werking van lixisenatide (een nieuw, op darmhormoon gebaseerd diabetes medicijn) en insuline glulisine (een veelgebruikt gangbaar diabetes medicijn) op de nierfunctie (EUDRACT) - Aug 19, 2014
P4, N=40, Ongoing, Sponsor: VU University Medical Center
- Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date: Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying (clinicaltrials.gov) - Aug 7, 2014
P2, N=26, Recruiting, Sponsor: Profil Institut f
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2014 Trial primary completion date: Jul 2014 --> Oct 2014
- |||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open, Combination therapy: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine (clinicaltrials.gov) - Aug 4, 2014
P4, N=148, Recruiting, Sponsor: Sanofi
Trial primary completion date: Jul 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- ||||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P4 trial, Combination therapy: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine (clinicaltrials.gov) - Jul 27, 2014
P4, N=148, Not yet recruiting, Sponsor: Sanofi
- | Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Phase classification: Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin (clinicaltrials.gov) - Jul 17, 2014
P2, N=142, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Phase classification: P2/3 --> P2
- ||||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi, Apidra (insulin glulisine) / Sanofi
Enrollment closed: GetGoal Duo-2: Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (clinicaltrials.gov) - Jul 17, 2014
P3, N=855, Active, not recruiting, Sponsor: Sanofi
Phase classification: P2/3 --> P2 Recruiting --> Active, not recruiting
- Adlyxin (lixisenatide) / Sanofi
New P3 trial, Combination therapy: LixiBIT: Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin (clinicaltrials.gov) - Jun 22, 2014
P3, N=10, Not yet recruiting, Sponsor: Medical University of Vienna
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes (clinicaltrials.gov) - May 21, 2014
P1, N=24, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date, Monotherapy: Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes (clinicaltrials.gov) - May 14, 2014
P3, N=360, Recruiting, Sponsor: Sanofi
Recruiting --> Completed Trial primary completion date: May 2015 --> Mar 2015
- ||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion date, Monotherapy: Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes (clinicaltrials.gov) - May 14, 2014
P3, N=360, Recruiting, Sponsor: Sanofi
Trial primary completion date: May 2015 --> Mar 2015 Trial completion date: May 2015 --> Mar 2015
- Victoza (liraglutide) / Novo Nordisk
Enrollment closed: LIRA-LIXI (clinicaltrials.gov) - May 13, 2014
P4, N=400, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: May 2015 --> Mar 2015 Recruiting --> Active, not recruiting
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial initiation date: Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin (clinicaltrials.gov) - May 5, 2014
P3, N=451, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Initiation date: Jan 2012 --> Feb 2012
- |||||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: LixiLan-O: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (clinicaltrials.gov) - Feb 17, 2014
P3, N=1125, Recruiting, Sponsor: Sanofi
Initiation date: Jan 2012 --> Feb 2012 Not yet recruiting --> Recruiting
- |||||||||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P3 trial: LixiLan-O: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (clinicaltrials.gov) - Feb 5, 2014
P3, N=1125, Recruiting, Sponsor: Sanofi
- | Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying (clinicaltrials.gov) - Feb 3, 2014
P2, N=26, Recruiting, Sponsor: Profil Institut f
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P4 trial: Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes (clinicaltrials.gov) - Jan 27, 2014
P4, N=12, Recruiting, Sponsor: University of Surrey
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: Study on Lixisenatide and Counterregulation to Hypoglycemia (clinicaltrials.gov) - Dec 18, 2013
P4, N=18, Recruiting, Sponsor: Lund University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P4 trial: Study on Lixisenatide and Counterregulation to Hypoglycemia (clinicaltrials.gov) - Dec 15, 2013
P4, N=18, Recruiting, Sponsor: Lund University
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P2 trial: The LIXI trial is aiming to recruit individuals with type 1 diabetes who are using insulin to control their disease. The trial is investigating whether a daily injection of a newly-licenced drug called lixisenatide, taken alongside a person's usual insulin medication can improve blood sugar levels after meals. (EUDRACT) - Dec 2, 2013
P2, N=33, Ongoing, Sponsor: University of Oxford
- |||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open, Monotherapy: Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes (clinicaltrials.gov) - Nov 11, 2013
P3, N=360, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Victoza (liraglutide) / Novo Nordisk
New P4 trial: LIRA-LIXI (clinicaltrials.gov) - Oct 29, 2013
P4, N=400, Recruiting, Sponsor: Novo Nordisk A/S
- Victoza (liraglutide) / Novo Nordisk
Enrollment open: LIRA-LIXI (clinicaltrials.gov) - Oct 24, 2013
P4, N=400, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P3 trial, Monotherapy: Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 8, 2013
P3, N=360, Recruiting, Sponsor: Sanofi
- |||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open, Combination therapy: Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes (clinicaltrials.gov) - Sep 15, 2013
P3, N=292, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P3 trial, Combination therapy: Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes (clinicaltrials.gov) - Sep 10, 2013
P3, N=292, Recruiting, Sponsor: Sanofi
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed: ELIXA: Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (clinicaltrials.gov) - Aug 29, 2013
P3, N=6000, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin (clinicaltrials.gov) - Aug 4, 2013
P2/3, N=142, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P2 trial: Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying (clinicaltrials.gov) - Jul 25, 2013
P2, N=26, Recruiting, Sponsor: Profil Institut f
- ||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin (clinicaltrials.gov) - Jul 1, 2013
P3, N=400, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P3 trial: GetGoal-O: Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (clinicaltrials.gov) - Feb 24, 2013
P3, N=340, Recruiting, Sponsor: Sanofi
- |||||||||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi, Apidra (insulin glulisine) / Sanofi
New P3 trial: GetGoal Duo-2: Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (clinicaltrials.gov) - Jan 13, 2013
P3, N=855, Recruiting, Sponsor: Sanofi
- |||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin (clinicaltrials.gov) - Nov 7, 2012
P3, N=432, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P3 trial: Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin (clinicaltrials.gov) - Jun 28, 2012
P3, N=432, Recruiting, Sponsor: Sanofi
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes (clinicaltrials.gov) - May 10, 2012
P1, N=24, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P2/3 trial: Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin (clinicaltrials.gov) - May 9, 2012
P2/3, N=142, Completed, Sponsor: Sanofi
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P1 trial: Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes (clinicaltrials.gov) - Apr 4, 2012
P1, N=24, Recruiting, Sponsor: Sanofi
- |||||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P3 trial: Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin (clinicaltrials.gov) - Jan 23, 2012
P3, N=400, Completed, Sponsor: Sanofi
- ||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: GetGoal-M-Asia: Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (clinicaltrials.gov) - Jan 11, 2012
P3, N=391, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed